Glenmark to Pay $25 Million in False Claims Settlement

Glenmark Pharmaceuticals Inc. USA has agreed to pay $25 million to resolve allegations of violating the False Claims Act. The settlement, announced Wednesday by the U.S. Department of Justice, stems from accusations that the New Jersey-based company engaged in price-fixing of a popular generic cholesterol medication.

The Justice Department alleged that between 2013 and 2015, Glenmark participated in a scheme to manipulate the market for pravastatin, a widely prescribed drug used to treat high cholesterol and triglyceride levels. The company reportedly colluded with other pharmaceutical manufacturers to fix prices, allocate customers, and control the supply of the drug.

This civil settlement comes on the heels of a related criminal case. Glenmark had previously entered into a deferred prosecution agreement with the Justice Department's Antitrust Division, admitting to criminal charges and paying a $30 million penalty. The additional $25 million civil settlement underscores the government's multi-pronged approach to combating fraud in the pharmaceutical industry.

Principal Deputy Assistant Attorney General Brian M. Boynton emphasized the far-reaching consequences of such practices, stating, "Illegal collaboration on the price or supply of drugs increases costs both to federal health care programs and beneficiaries."

The case highlights the ongoing issue of rising drug costs in the United States. U.S. Attorney Jacqueline C. Romero of the Eastern District of Pennsylvania noted, "At a time when excessive drug costs are already imposing unprecedented burdens on our country's vulnerable citizens, an illegal conspiracy to fix the prices of generic drugs is alarming."

Health care fraud experts point out that this settlement is part of a broader investigation into price-fixing among generic drug manufacturers. It marks the sixth resolution in this ongoing probe, signaling the Justice Department's commitment to rooting out anticompetitive practices in the pharmaceutical industry.

The investigation involved multiple agencies, including the Department of Health and Human Services Office of the Inspector General and the Defense Criminal Investigative Service. This collaborative effort underscores the government's determination to protect federal health care programs like Medicare and TRICARE from financial abuse.

As the pharmaceutical industry faces increased scrutiny, this case serves as a stark reminder of the legal and financial risks companies face when engaging in anticompetitive practices. It also raises questions about the effectiveness of current regulations in preventing such behavior and ensuring fair pricing in the generic drug market.

The $25 million settlement, while significant, was based on Glenmark's ability to pay, suggesting that the full extent of the alleged fraud may have warranted an even larger penalty. This aspect of the settlement may fuel ongoing debates about the adequacy of corporate penalties in deterring future misconduct.

As this case concludes, attention now turns to how it might influence future behavior in the pharmaceutical industry and whether it will lead to more robust oversight and regulation of generic drug pricing.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.